Chimerix (NASDAQ:CMRX) Downgraded by StockNews.com to "Sell"

Chimerix (NASDAQ:CMRX - Get Free Report) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued on Friday.

Several other equities research analysts have also recently weighed in on the company. Wedbush reiterated an "outperform" rating and issued a $6.00 price objective on shares of Chimerix in a report on Monday, February 12th. HC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of Chimerix in a report on Friday, March 1st.

Chimerix Stock Performance

Shares of Chimerix stock remained flat at $0.95 on Friday. 158,258 shares of the stock traded hands, compared to its average volume of 382,576. The firm has a 50 day moving average of $1.05 and a 200-day moving average of $1.00. Chimerix has a 1 year low of $0.88 and a 1 year high of $1.57. The firm has a market cap of $85.41 million, a PE ratio of -1.02 and a beta of 1.13.

Chimerix (NASDAQ:CMRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.04). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 39.62%. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. On average, equities analysts anticipate that Chimerix will post -0.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CMRX. Bank of New York Mellon Corp grew its stake in Chimerix by 190.0% in the third quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company's stock worth $568,000 after purchasing an additional 387,638 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Chimerix by 167.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 426,672 shares of the biopharmaceutical company's stock worth $410,000 after buying an additional 267,044 shares during the period. Pale Fire Capital SE bought a new position in shares of Chimerix in the 3rd quarter worth about $95,000. RA Capital Management L.P. purchased a new position in Chimerix during the 3rd quarter valued at about $6,240,000. Finally, Vance Wealth Inc. purchased a new position in Chimerix during the 4th quarter valued at about $46,000. Institutional investors own 45.42% of the company's stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.